Your browser doesn't support javascript.
loading
Predictors of fluid overload in allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide.
Tsao, Megan; Hoeg, Rasmus; Pecoraro, Joshua; Kuehner, Megan; Deen, Brittany; Guglielmo, Julie.
Affiliation
  • Tsao M; University of California, Davis Health (UCDH), Sacramento, CA, USA.
  • Hoeg R; University of California, Davis Health (UCDH), Sacramento, CA, USA.
  • Pecoraro J; University of California, Davis Health (UCDH), Sacramento, CA, USA.
  • Kuehner M; University of California, Davis Health (UCDH), Sacramento, CA, USA.
  • Deen B; University of California, Davis Health (UCDH), Sacramento, CA, USA.
  • Guglielmo J; University of California, Davis Health (UCDH), Sacramento, CA, USA.
J Oncol Pharm Pract ; : 10781552241276418, 2024 Aug 18.
Article in En | MEDLINE | ID: mdl-39155604
ABSTRACT

BACKGROUND:

Fluid overload (FO) commonly occurs during hospitalization for allogeneic hematopoietic cell transplantation (HCT). Grade 2-4 FO is associated with day +100 non-relapse mortality.1 Post-transplant cyclophosphamide (PTCY) for graft-versus-host disease prevention requires aggressive IV hydration to prevent hemorrhagic cystitis. MATERIALS AND

METHODS:

This is a single-center, retrospective, observational study conducted at an academic medical center via electronic chart review. Included patients received allogeneic HCT followed by PTCY on days +3 and +4. Patients were excluded for age < 18 years or incarceration. Primary endpoints are incidence of Grade 2-4 FO and associated risk factors. Descriptive and inferential statistics (i.e., Fisher's exact test, multivariable regression analysis) were used.

RESULTS:

Of 97 patients screened, 95 were included and 2 were excluded due to absence of weight measurements needed to grade FO. Median age was 60 years, 66.3% were male, 91.6% received reduced-intensity conditioning, 72.6% received haploidentical HCT, 44.2% were ECOG 0, and 11.6% had diastolic dysfunction. Incidence of grade 2-4 FO was 33.7% (n = 32). Univariate analyses found age (continuous; p = 0.04) and BSA < 1.7 m2 (p = 0.006) as independent factors associated with grade 2-4 FO. Multivariable regression analysis found 3.3% higher risk with every 1-year increase in age ranging from f 20 to 78 years (OR 1.033, 95% CI 1.001, 1.006; p = 0.0453) and 82.8% lower risk with BSA ≥ 1.7 m2 (OR 0.172, 95% CI 0.051, 0.588; p = 0.005) after adjusting for co-variates. CONCLUSION(S) Increasing age and BSA < 1.7 m2 are risk factors associated with grade 2-4 FO during hospitalization for allogeneic HCT with PTCY.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Oncol Pharm Pract Journal subject: FARMACIA Year: 2024 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Oncol Pharm Pract Journal subject: FARMACIA Year: 2024 Document type: Article Affiliation country: Country of publication: